HENGRUI PHARMA (01276) News

Express News | Hengrui Pharma: Clinical Trial Approval for HRS9531 Injection

BreakingsMar 9 17:27

HKEX Announcements Digest | Tanwan's net profit exceeds 1.5 billion yuan in 2025, Huaying Construction subsidiary wins a construction project worth 3.6 billion Hong Kong dollars

① What is the year-on-year increase in Tanwan's net profit exceeding 1.5 billion yuan in 2025? ② A subsidiary of Huaying Construction has won a construction project worth 3.6 billion Hong Kong dollars. What are the details?

cls.cnMar 9 20:17

Express News | Hengrui Pharma: Subsidiary Receives Clinical Trial Approval Notice for HRS9531 Injection

BreakingsMar 9 17:23

Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables

MT NewswiresMar 9 15:40

H-share announcements highlight | Mengniu Dairy expects its annual profit attributable to shareholders to be approximately RMB 1.4 billion to RMB 1.6 billion.

Xuanzhu Bio-B has been included in the list of eligible stocks for Stock Connect; Changfeng Pharmaceuticals has been added to the list of eligible securities for both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.

Zhitong FinanceMar 9 09:03

Hong Kong Stock Exchange Announcements Highlights | HuiShang Bank Reports Over 16.9 Billion Yuan in Net Profit for 2025, Welltech Holdings' Annual Profit Surges More Than 40% Year-on-Year

① HSB Bank is expected to generate a net profit of over 16.9 billion yuan in 2025. What is the growth rate? ② Wasion Holdings' annual profit increased by more than 40% year-over-year. What is the scale?

cls.cnMar 6 20:15

Zhitong HK Stock Short Position Statistics | March 6

Zhitong HK Stock Short Position Report | March 6

Zhitong FinanceMar 6 18:30

Hengrui Pharma (01276): Adebrelimab Injection Receives Approval for Clinical Trial Notification

Hengrui Pharma (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has recently received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration for the drug Adebrelimab Injection. The clinical trial will commence shortly.

Zhitong FinanceMar 6 17:46

Express News | Hengrui Pharma: Subsidiary receives clinical trial approval notices for Adebrelimab Injection and SHR-8068 Injection.

BreakingsMar 6 17:06

The Hang Seng Index closed up 435 points. JD.com surged 10%, while JD Logistics skyrocketed 23%.

The Hong Kong stock market performed well, driven by technology stocks. The Hang Seng Index opened 37 points higher and extended its gains, rising by 485 points at one point to reach an intraday high of 25,806 points. It closed up 435 points, or 1.7%, at 25,757 points. The China Enterprises Index rose 176 points, or 2.1%, to close at 8,628 points, while the Hang Seng Tech Index gained 151 points, or 3.2%, closing at 4,947 points. Total turnover for the day amounted to HKD 292.766 billion. Following their earnings announcements, JD.com (09618.HK) surged 10% to close at HKD 106.60, while JD Logistics (02618.HK) soared 23% to close at HKD 12.63, becoming the top performer on the blue-chip board.

AASTOCKSMar 6 16:31

Hong Kong Stock Market Midday Review | Hang Seng Index rose 1.84% in the morning session, while the Hang Seng Innovative Drug Index surged 4.5%.

The biopharmaceutical industry has entered the list of "emerging pillar industries" for the first time, with both BD and performance expected to serve as dual growth drivers.

Zhitong FinanceMar 6 12:00

The concept of innovative pharmaceuticals in Hong Kong stocks has gained momentum, with biomedicine emerging as a 'new pillar industry' for the first time. Both business development (BD) and financial performance are expected to serve as dual drivers.

The innovative drug sector strengthened during early trading. As of press time, 3SBio Inc. surged nearly 9%, Hutchison China MediTech rose over 8%, Innovent Bio climbed nearly 6%, Hengrui Pharma increased more than 5%, and Connaught Medical-B gained 5%.

Zhitong FinanceMar 6 10:22

Express News | The innovative pharmaceutical concept stocks in the Hong Kong stock market collectively rose, with Hutchison China MediTech up over 7%, 3SBio Inc. up over 5%, Siho Pharma and Innovent Bio up over 4%, Hengrui Pharma up nearly 4%, and Akeso Biopharma up ove

BreakingsMar 6 09:48

Stock Movement | Hengrui Pharma (01276) Surges Over 6% as Two Injectable Solutions Approved for Clinical Trials, Set to Begin Soon

Hengrui Pharma (01276) surged over 6%. As of the latest update, it rose by 6.15%, trading at HKD 63.9 with a turnover of HKD 113 million.

Zhitong FinanceMar 5 10:44

H-share Announcement Highlights | Uni-President China Holdings Limited's profit attributable to shareholders for 2025 increased by 10.88% year-on-year to RMB 2.05 billion, with a final dividend of RMB 0.4747 per share.

Binhai Investment (02886) received increased investment from Tianjin Teda and Sinopec, furthering its natural gas and clean energy strategy.

Zhitong FinanceMar 5 09:15

Hong Kong Stock Announcements Highlights | Uni-President China's Net Profit Exceeds 2 Billion Yuan in 2025, Chizi City Technology's Annual Profit Increases by Approximately 90% Year-on-Year

① Uni-President China's net profit exceeded 20 billion yuan in 2025. What is the growth rate? ② Chuzi City Technology's annual profit increased by approximately 90% year-over-year. What are the highlights?

cls.cnMar 4 20:19

Hengrui Pharma (01276): SHR-A2102 for injection and SHR-8068 injection have received approval notices for clinical trials.

Hengrui Pharma (01276) announced that recently, its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Hengrui Pharma Co., Ltd., received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration for the drugs SHR-A2102 for injection and SHR-8068 injection. Clinical trials are expected to commence shortly.

Zhitong FinanceMar 4 17:13

Hengrui Pharma (01276.HK): HRS-1780 tablets receive clinical trial approval

Gelonghui, March 4th ─ Hengrui Pharma (01276.HK) announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has recently received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration for HRS-1780 tablets, and clinical trials will commence shortly. According to the disclosure, HRS-1780 tablets are mineralocorticoid receptor antagonists intended for the treatment of primary aldosteronism. The first-line treatment for primary aldosteronism is mineralocorticoid receptor antagonists. Currently, only spironolactone has been approved, but it is associated with sex hormone-related side effects.

Gelonghui FinanceMar 4 17:05

Share Repurchase Roundup on March 3 | Xiaomi Group-W, Geely Auto, and others conducted share repurchases, with Xiaomi Group-W spending HKD 99,996,300.

According to the disclosure document of the Hong Kong Exchange on March 4, companies such as Xiaomi Group-W (01810.HK) and Geely Auto (00175.HK) repurchased shares. ① Xiaomi Group-W (01810.HK) repurchased 3.1564 million dual-class shares on March 3, involving an amount of HKD 99.9963 million, with the repurchase price per share ranging from HKD 31.76 to HKD 31.6. Since the resolution authorizing the repurchase, the cumulative number of repurchased securities has reached 260 million shares, accounting for 1.0% of the total number of issued shares at the time of the ordinary resolution's passage. ② Geely Auto (00175

Futu NewsMar 4 08:50

Hengrui Pharma (01276.HK) repurchased 630,000 A-shares at a cost of 33.9821 million yuan on March 3.

Gelonghui, March 3rd: Hengrui Pharma (01276.HK) announced that on March 3, 2026, it repurchased 630,000 A-shares for RMB 33.9821 million at a price of RMB 53.52 to 54.27 per share.

Gelonghui FinanceMar 3 17:05